The Journal of Pediatrics
Volume 156, Issue 2 , Pages 302-307 , February 2010

Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids

  • Deborah M. Levy, MD, MS

      Affiliations

    • Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY
    • Corresponding Author InformationReprints not available. Correspondence to Dr Deborah Levy, Morgan Stanley Children's Hospital of New York-Presbyterian, 3959 Broadway, CHN 106, New York, NY 10032.
    • ,
  • C. April Bingham, MD

      Affiliations

    • Department of Pediatrics, Milton S. Hershey Medical Center, Penn State College of Medicine, College Station, PA
    • ,
  • Philip J. Kahn, MD

      Affiliations

    • Department of Pediatrics, New York University School of Medicine, New York, NY
    • ,
  • Andrew H. Eichenfield, MD

      Affiliations

    • Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY
    • ,
  • Lisa F. Imundo, MD

      Affiliations

    • Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY

Received 2 March 2009 ,Revised 6 August 2009 ,Accepted 2 September 2009.

References 

  1. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103:882–888
  2. Reed AM, Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs. 2002;4:315–321
  3. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. 1992;35:1143–1149
  4. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570–3578
  5. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19:138–141
  6. Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis: experience and longterm followup of 6 cases. J Rheumatol. 1996;23:1424–1427
  7. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24:2436–2443
  8. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16:1545–1547
  9. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592–600
  10. Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1:1063–1066
  11. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000
  12. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–2375
  13. Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, et al. Limited effects of high-dose intravenous immunoglobulin (IVIg) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis. 2007;66:1276–1283
  14. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991;91:169–172
  15. Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis]. Ned Tijdschr Geneeskd. 1993;137:1979–1982
  16. Tsai MJ, Lai CC, Lin SC, Chiang BL, Chou CC, Hsieh KH. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1997;38:111–115
  17. Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P. Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol. 1996;15:215–216
  18. Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int. 1999;41:696–697
  19. Roifman CM. Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J Clin Immunol. 1995;15:42S–51S
  20. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child. 1995;72:25–28
  21. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27:2498–2503
  22. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–347
  23. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–407
  24. Plamondon S, Dent PB. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol. 2000;27:2031–2034
  25. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum. 1987;30:328–334
  26. Eisenstein DM, Paller AS, Pachman LM. Juvenile dermatomyositis presenting with rash alone. Pediatrics. 1997;100:391–392
  27. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148:247–253
  28. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RN, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43:541–549
  29. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28:833–857
  30. Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008;121:e626–e630
  31. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004;50:1595–1603
  32. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59:4–13

 The authors declare no financial or other relationships that might lead to a conflict of interest

PII: S0022-3476(09)00876-2

doi: 10.1016/j.jpeds.2009.09.008

The Journal of Pediatrics
Volume 156, Issue 2 , Pages 302-307 , February 2010

Article Tools

* Image Usage & Resolution